Risperidone side effects

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 8, 2000, Pages 20-25

  Conley, Robert R ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; OLANZAPINE; PERPHENAZINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN 2 ANTAGONIST; THIORIDAZINE;

DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; HYPERPROLACTINEMIA; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REVIEW; TARDIVE DYSKINESIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPERPROLACTINEMIA; INCIDENCE; MOVEMENT DISORDERS; PIRENZEPINE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; WEIGHT GAIN;

EID: 0034082618     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Borison RL, Pathiraja AP, Diamond BI, et al. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-218
2. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40
3. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
4. Peuskens J, on behalf of the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-726
5. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35: 51-68
6. Wirshing DA, Marshall BD Jr, Green MF, et al. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry 1999;156:1374-1379
7. Sharif ZA. Treatment refractory schizophrenia: how should we proceed? Psychiatr Q 1998;69:263-281
8. Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 1995 10:207-213
9. Conley RR, Mahmoud R, and the Risperidone Study Group. Risperidone vs olanzapine in patients with schizophrenia and schizoaffective disorder. Presented at the annual meeting of the American College of Neuropsychopharmacology; Dec 12-16, 1999; Acapulco, Mexico
10. Ho C-C, Miller D, Nopoulos P, et al. A comparative effectiveness study of risperidone and planzapine in the treatment of schizophrenia. J Clin Psychiatry 1999;60:558-663
11. Risperdal [package insert]. Titusville, NJ: Janssen Pharmaceutica; May 1999
12. Lemmens P, Brecher M, Van Baelen B. A combined analysis of double-blind studies with risperidone vs placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 1999;99:160-173
13. Kane JM, Woerner M, Lieberman J, et al. Tardive dyskinesia: prevalence, incidence and risk factors. J Clin Psychopharmacol 1988;8(suppl): 52S-56S
14. Jeste DV, Rockwell E, Harris MJ, et al. Conventional vs newer antipsychotics in elderly patients. Am J Geriatr Psychiatry 1999;7:70-76
15. Guitierrez-Esteinou R, Grebb JA. Risperidone: an analysis of the first three years in general ase. Int Clin Psychopharmacol 1997;12(suppl 4):S3-S10
16. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997;58(suppl 10):55-62
17. Allison DB, Mentor JL, Heo M, et al. Weight gain associated with conventional and newer antipsychotics: a meta-analysis. In: New Research Program and Abstracts of the Annual Meeting of the American Psychiatric Association; June 3, 1998; Toronto. Canada. Abstract NR497:202
18. Miller DD. Review and management of clozapine side effects. J Clin Psychiatry 2000:61(suppl 8):14-17
19. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-783
20. Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999;40:438-443
21. Hagg S, Joelsson L, Mjomdal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998;59:294-293
22. Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999; 19:57-61
23. Klibanski A, Greenspan SL. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 1986;315:542-546
24. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
25. Daniel DG, Goldberg TE, Weinberger DR, et al. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 1996;153:417-419
26. McElroy SL, Keck PE Jr, Strakowski SM. Mania, psychosis, and antipsychotics. J Clin Psychiatry 1996;57(suppl 3):14-26
27. Dwight MM, Keck PE Jr, Stanton SP, et al. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder [letter]. Lancet 1994;344:554-555
28. Brecher MB, Lemmens P, van Baelen B. Tolerability and cardiovascular safety of risperidone. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association; May 21, 1997; San Diego, Calif. Abstract NR612:233